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a b s t r a c t
Anti-cancer drugs are an important class of pharmaceutical products. Methotrexate (MTX)
is a folic acid antagonist used in high doses as antimetabolite in anti-cancer treatment as
well as in low doses for the treatment of rheumatoid arthritis and adults’ psoriasis. In the
past, several anti-cancer drugs, including methotrexate, have been found in the environ-
ment. Their presence in water, especially if used for the production of drinking water, is
even in low concentrations of particular interest, due to the risk to retrieve them in the
consumed water and their high activity and grave effects. But prior to usage as drinking
water, raw waters are treated and chlorination is a common practice in several countries.
As such a treatment can lead to the formation of organochlorine in water, the study of the
fate of MTX during chlorination in a batch trial was carried out. The reaction was moni-
tored by dissolved organic carbon (DOC) and by ﬂuorescence and UV spectroscopy.
Investigation of by-products formed was done with liquid chromatography/mass spec-
trometry (LC/MS). Under the given experimental conditions, Methotrexate was eliminated
rapidly (t1/2 around 21 min). However, DOC elimination was incomplete. Monitoring with
LC-MS showed the formation of a monochlorinated transformation product of MTX.
In silico analysis of the proposed transformation products for different carcinogenic,
mutagenic and genotoxic endpoints with different software platforms provided no clear
evidence that the possible transformation products after chlorination might be more toxic
than the parent compound. However, since a number of alerts is altered after chlorination,
it cannot be excluded that the toxicity of these transformation products might be modu-
lated compared with the parent compound.
ª 2014 Elsevier Ltd. All rights reserved.
1. Introduction
In the last decade the presence of pharmaceuticals, ranging
from nanograms to a few micrograms per liter, has been
reported in the aquatic cycle including surface water, waste-
water and groundwater (Besse and Garric, 2008; Buerge et al.,
2006; Kasprzyk-Hordern et al., 2008; Lo´pez-Serna et al., 2012;
Osorio et al., 2012; Petrovic et al., 2012; Ratola et al., 2012;
Roberts and Thomas, 2006; Verlicchi et al., 2012) and, to a
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lesser extent, drinking water (De Jongh et al., 2012; Mompelat
et al., 2011; Wang et al., 2011a). Advances in analytical in-
struments have been a key factor driving their increased
detection (Ferrer and Thurman, 2012; Grabic et al., 2012; Gros
et al., 2012).
As for other micro-pollutants, their presence in environ-
mental water, even at these very low concentrations, has
raised particular interest. It points out the need to verify the
efﬁcacy of drinkingwater treatment processes for the removal
of such compounds (Stackelberg et al., 2004; Westerhoff et al.,
2005).
Drinking water treatment consists of several steps
including ﬁltration, ﬂocculation, sedimentation and disinfec-
tion. Some treatment facilities also include ion exchange and
adsorption onto activated carbon. Depending on the country,
disinfection (chlorination, ozonation, UV radiation) is gener-
ally applied before the water enters the distribution system as
drinking water to ensure elimination of potentially dangerous
microbes (Gibs et al., 2007; Stackelberg et al., 2004). Ozonation
and UV radiation are considered as powerful and effective
disinfectant respectively. Contrary to ozonation and UV
treatment whose remanence is very short, chlorination by
treatment with chlorine, chlorine dioxide and sometimes
chloramines is more often used because of its effectiveness in
the treatment plant and its lasting presence and activity in the
distribution network, although formation of harmful trans-
formation products could be observed (Cantor et al., 1998;
Hamidin et al., 2008; Meier et al., 1983).
Among various classes of pharmaceuticals, anti-cancer
drugs are of particular environmental concern because they
are potentially carcinogenic, mutagenic and genotoxic, even
at low concentrations (Zounkova´ et al., 2007) and reveal low
biodegradability (Baumann and Preiss, 2001; Buerge et al.,
2006; Straub, 2010). Methotrexate (MTX) is an analogous of
folic acid and inhibits the enzyme Dihydrofolate reductase. It
is used in chemotherapy at high doses and at low doses in the
treatment of some autoimmune diseases like rheumatoid
arthritis, adult psoriasis or ectopic pregnancy. With intrave-
nous administration, 80e90% of the administered dose is
excreted unchanged in the urine within 24 h (Drug Bank). It
enters the environment via urban wastewaters (Castiglioni
et al., 2006, 2005; Catastini et al., 2008), hospital wastewaters
(Aherne et al., 1985; Yin et al., 2010) and can be detected even
in drinking water (Aherne et al., 1985).
Though the effect of chlorination has been investigated for
a number of pharmaceutical products in wastewater (Bedner
and MacCrehan, 2006; Hey et al., 2012; Lee and von Gunten,
2010; Li and Zhang, 2012), surface water (Meyer et al., 2002;
Shah et al., 2006; Wang et al., 2011b) and pure water (Li
et al., 2011; Mash, 2010; Quintana et al., 2010; Rodil et al.,
2012; Soufan et al., 2012), anti-cancer drugs in general and
MTX in particular have received very low attention despite
their high activity, possible promotion of cancer and terato-
genic risk. The only anti-cancer drug yet investigated is
cyclophosphamide (Besse et al., 2012; Huber et al., 2005;
Ku¨mmerer and Al-Ahmad, 2010; Mompelat et al., 2011).
Experimental toxicity testing of identiﬁed transformation
products (TP) is often difﬁcult, since many of them are not
available commercially. Computer models calculating quan-
titative structure activity relationship (QSAR) are important
tools to overcome this limitation. Once structure elucidation
of any TP has been performed, these structures can be
investigated using QSAR programs in order to predict the toxic
potential of TPs for different toxicological endpoints and other
environmental parameters. A set of programs for predicting
biodegradation should be applied in order to take into account
that the available programs might have individual strengths
because of different algorithms and training sets.
The main aim of this study was to monitor the fate of MTX
during chlorination (by using spectroscopic methods) with
regard to the possible formation of transformation products
(by LC/MS).
2. Materials and methods
2.1. General methodology
Chlorinationwas performed during 5 h at 21 3 Cwith initial
pH of 8.6 (decreasing to pH 7.6 during reaction due to hydro-
chloric acid production). Experiments were carried out in a
100 mL reactor. Working concentration of MTX was 1 mg/L in
pure water. Chlorine was added as sodium hypochlorite to
ensure a molar ratio MTX:Cl2 of 1:100. The resulting mixture
was stirred during 15e20 s to achieve a homogenous solution.
DOC (NF EN 1484), residual chlorine, and pHweremeasured to
follow the general progress of the chlorination. Samples were
taken and measured by UV-spectrophotometry in order to
simply follow the kinetics of MTX removal. The relative MTX
concentration variation was assessed by ﬂuorescence after
photooxidation of the chlorinated sample. Finally, LC/MS was
used for a preliminary monitoring of possibly formed trans-
formation products.
2.2. Material
For basic measurements, pH was measured with an electrode
(pHenomenal pH 1000 L). A DPD comparator disk kit CIFEC
was used for residual chlorine quantiﬁcation. DOC was
measured following chemical oxidation with sodium persul-
fate using a TOC-meter (OI Analytical 1010).
Qualitative assessment of MTX degradation was followed
by UV-spectrophotometry (Lambda 35 Perkin Elmer) using a
100 mm quartz circulation cell connected with a closed loop
circuit. Scan speed of wavelength range (200e400 nm with
step width of 1 nm and a lamp change at 326 nm) was ﬁxed at
1920 nm/min. A spectrum was acquired every minute.
Fluorescence spectra were measured with a Xenius spec-
troﬂuorometer (Safas, Monaco) equipped with a 1 cm quartz
cell. Fluorescence was measured at 462 nmwith an excitation
wavelength of 380 nm. The photomultiplier (PM) voltage was
generally set at 700 V andmoved to 600 and 500 V according to
the signal saturation.
Photooxidation followed by ﬂuorescence measurement
was used to assess the concentration of MTX during the
chlorination. The photooxidation was performed by using the
OXI50 device of Secomam (Ale`s, France) equipped with a low
pressure mercury lamp emitting mainly at 185 and 254 nm
and permitting direct photolysis of molecule. For this purpose











the sample was introduced into a 0.5 cm quartz cuvette (vol-
ume 1 ml) and was irradiated 40 s before ﬂuorimetry analysis.
Preliminary observation of transformation products was
carried out by rapid resolution liquid chromatography coupled
to mass spectrometry in tandem (LC/MS). The system con-
sisted of Agilent LC 1200 Inﬁnity LC equipped with an auto-
sampler, column oven, and pumps. Separationwas performed
on a Zorbax Eclipse Plus C18 column (100 mm  2.1 mm 
1.8 mm, Agilent Technologies, Prague, Czech Republic), at 50 C
(column oven). Its proﬁle, at a ﬂow rate of 0.4 mL/min was in
gradient mode and the mobile phases were water acidiﬁed
with 0.01% formic acid (phase A) and acetonitrile (phase B).
The initial composition of the mobile phase was 95% A (5% B)
maintained for 3 min, then 70% A (30% B) maintained for
6 min, then 10% A (90% B) maintained for 1 min, then 90% A
(10% B) maintained for 3 min and ﬁnally the initial conditions
for 2 min.
The liquid chromatography was coupled with an
electrospray ionization source to an Agilent 6460 Triple
Quadrupole mass spectrometer equipped with electrospray
jet stream technology operating in positive mode. The in-
strument was operated with the capillary voltage at þ4 kV,
and nozzle voltage at 500 V. Nitrogen was used as nebulizer
gas of 45 psi, a drying gas of 5 l/min at 200 C and a sheath
gas of 11 l/min at 250 C. A full scan (5,200 amu/s) ranging
from m/z 50 to 600 with a fragmentor voltage of 150 V was
used for preliminary monitoring of transformation products.
2.3. Chemicals and solvents
Methotrexate was purchased from Sigma Aldrich (St Quentin
Fallavier, France) and was in powder form with purity >99%.
Three years of stability if stored at 20 C was guaranteed by
certiﬁcate. Acetonitrile (HPLC grade) was purchased from J.T
Baker (Atlantic Labo ICS Bruges, France), formic acid (purity of
99%) fromCarlo Erba (Val de Reuil, France). Fenuron (CAS: 101-
42-8; purity>99%) was purchased from VWR (Fontenay sous
Bois, France; certiﬁed quality, from Dr. Ehrenstorfer GmbH,
Augsburg, Germany). Sodium sulﬁte was bought from Merck.
Pure water was produced using a Milli-Q water system (Mil-
lipore, Molsheim, France). Chlorine was supplied from 250 mL
of concentrated sodium hypochlorite (9.6% of active chlorine)
(Oxena, Portes les Valence, France). Stock solutions of MTX
were prepared at a concentration of 50 mg/L in pure methanol
and stored in darkness at 5 C. Individual working solutions
were prepared freshly at the day of experiments at 1 mg/L in
pure water by dilution of stock solutions. Chlorine solution
was prepared at 1 g/L (free chlorine) by diluting commercial
sodium hypochlorite in pure water. The concentration of re-
sidual chlorine in this solution was veriﬁed everyday by so-
dium thiosulfate titration. After chlorination, reaction
between chlorine and MTX was stopped with a molar excess
of sodium sulﬁte (Na2S2O3/Cl2 ¼ 3/1) before analysis.
2.4. Analysis
Fluorimetric quantiﬁcation of MTX was based on works
already described in the literature and dealing with the pho-
totransformation (generally, in the presence of H2O2) of MTX
which is originally weakly ﬂuorescent, into the more ﬂuores-
cent substance 2,4-diamino-pteridine-6-carboxylic acid (Lu
and Juna, 1995; Salamoun et al., 1987; Uchiyama et al., 2012).
In our study, due to the power of the UV lamp (irradiation
band at 185 nm) and the presence of chlorine, the photo-
transformation was performed without addition of H2O2
during 40 s. Quantiﬁcation of MTX was performed by ﬂuo-
rimetry after photooxidation. Conﬁrmation of the measure-
ment speciﬁcity was done for several times of chlorination
with HPLC/MS (data not shown).
2.5. In silico analysis of proposed transformation
products
MTX and its possible chlorination TPs were assessed by a set
of in silico predictions for toxicity. This takes into account that
the available programs might have individual strengths
because of different algorithms and training sets. The set of
available programs was Case Ultra V 1.4.5.1 (MultiCASE Inc.)
(Saiakhov et al., 2013), the Oasis Catalogic software V.5.11.6 TB
from Laboratory of Mathematical Chemistry, University
Bourgas, Bulgaria and Leadscope software V. 3.0.11-1 with
training sets from 2012 SAR Genetox Database provided by
Leadscope (Roberts et al., 2000). Structure illustrations were
performed by using MarvinSketch 5.8.0. Simpliﬁed molecular
input line entry speciﬁcation (SMILES) codes from the molec-
ular TP structureswere used for input of molecular structures.
Genotoxicity, mutagenicity and carcinogenicity were
predicted with Case Ultra using the following QSAR
models: Human Carcinogenicity (AOJ), Aneuploidy in Yeast
(A6A), Micronucleus Formation in vivo composite (A7S),
Fig. 1 e Fluorescence of MTX in the presence of chlorine. A: Before photochemical oxidation (PM 700V); B: After
photochemical oxidation (PM 500 and 600V).











Micronucleus Formation in vivo Mouse (A7T), Chromosomal
Aberrations in vitro composite (A7U), Chromosomal Aberra-
tions in vitro CHO cells (A7T), Rat Carcinogenicity (AOD),
Mouse Lymphoma (ML), Mouse Carcinogenicity (AO8), Muta-
genicity Ames (A2H) (Salmonella Ames mutagenicity updated
from NTP, Genetox, FDA and others. It consists of the Salmo-
nella typhimurium strains TA97, TA98, TA100, TA102, TA104,
TA1535eTA1538 using a different training set compared with
A7B), Unscheduled DNA Synthesis (UDS) Induction (A64).
CASE Ultra predicts positive or negative structural alerts.
Additional conclusions were “Out of Domain” e when an
unknown structural fragment was found in the test chemical
which excludes it from the chemical space of the training set
of the applied model; “Inconclusive” (IN) e a signiﬁcant
portion of the test chemical is covered by unknown structural
fragments, “Inconclusive” (IN(P)) e both positive and deacti-
vating alerts were found in the same molecule.
Oasis Catalogic software predicted mutagenicity based on
bacterial mutagenicity (module mutagenicity v.04) in S.
typhimurium (Salmonella Catalogic model, SC).
Leadscope software predicted genotoxicity and mutage-
nicity using the following four QSARmodules: In vitro chromo-
some aberration composite (IVCA) Mammalian mutagenesis
(MM), In vivomicronucleus (IVMN), bacterial mutagenesis (BM).
3. Results and discussion
3.1. Monitoring of MTX
In the presence of chlorine (during the chlorination), MTX
natural ﬂuorescence spectrum is modiﬁed (Fig. 1A) with the
appearance of a broad peak between 420 and 520 nm.
ConsequentlyMTX can’t bemeasured directly in ﬂuorescence.
The photooxidation of the mixture MTX/Chlorine produces a
strong increase of the ﬂuorescence, with maximum absorp-
tion at 464 nmwhich was used for MTX quantiﬁcation. Fig. 1B
illustrates the necessity to modify the voltage of the photo-
multiplier (PM) to avoid signal saturation. The photo-
tochemical reaction coupled with the adjustment of the
ﬂuorescent signal allowed a better sensitivity of the method.
Fig. 1B also demonstrates the absence of interferences of
photooxidation of NaOCl or MTX alone.
Fig. 2 shows that MTX concentration can be accurately
determined by the method under these conditions. The cali-
bration of MTX measurement was performed by comparison
between expected (obtained from standard solutions) and
measured (obtained after ﬂuoro-photooxidation) concentra-
tions. Measured concentrations were obtained from the
response instrument (relative intensity) owing to a pre-
liminary calibration curve obtained at PM 500, 600 and 700
(data not shown).
3.2. Methotrexate chlorination
Fig. 3 shows the decrease of the concentration of MTX during
chlorination of a MTX solution of 1 mg/L in the presence of
chlorine in a molar ratio of 1:100. The experiment was per-
formed in duplicate.
Fig. 3 shows that a treatment of 120 min results in nearly
complete elimination of MTX (99.9%  0.014%). During this
time the reaction follows a kinetic of 1st order (lnC0/C ¼ f(t) is
linear) and the half life of MTX under the conditions applied
has been calculated as 20.6 min.
Chlorination was monitored by UV spectroscopy. Fig. 4
shows the UV spectra of the solution of 1 mg/L MTX,
Fig. 2 e Comparison of MTX measurement by ﬂuorimetry
with regard to expected (known concentration prepared
from standard solution) concentration (n [ 2).
Fig. 3 e MTX concentration decrease during chlorination
followed by ﬂuorimetry monitoring (n [ 2).
Fig. 4 e UV spectra of chorine, MTX and mixture (1 min
contact time).











15 mg/L chlorine and of the mixture, whose spectrum is a
combination of the spectra of chlorine and MTX solutions
alone, respectively, with an absorption maximum at 292 nm.
Moreover, methotrexate showed characteristic peaks and
shoulders at 222, 251, 302 (lmax) and 353 nm.
Under the operational conditions of chlorination, DOC
determined at the beginning of the chlorination and for mid-
reaction time, showed no signiﬁcant decrease of its 0.5 mg/L
initial concentration. Chlorine concentration decreased
slowly during treatment period, between 15 and 20% and pH
dropped one unit from 8.6 to 7.6.
The set of UV spectra acquired during chlorination is
characterized by a strong decrease of the absorbance at 292
and 263 nm and a slight increase of the absorbance at 220 and
360 nm (Fig. 5A). The presence of an isosbestic point at 247 nm
reveals that the chlorination of MTX is a simple reaction be-
tween two absorbing compounds or mixtures of compounds
(Pouet et al., 2004) characterized by a qualitative and quanti-
tative conservation, i.e. with a ﬁxed linear relationship be-
tween reagent(s) and product(s). In Fig. 5A, the reaction of
MTX chlorination is characterized by the decreasing intensity
of the spectrum of the mixture MTX/chlorine and the
Fig. 5 e UV monitoring of MTX chlorination. A: Raw UV spectra; B: modiﬁed UV spectra (chlorine contribution subtracted).
Fig. 6 e Behavior of MTX during chlorination in mass spectroscopy. Relative concentration corresponds to the ratio C0/C
(obtained by ﬂuorimetry after photooxidation); chromatograph peak at 7.4 min correspond to internal standard (n [ 2).











appearance of the spectrum of the residual chlorine and the
transformation product of MTX.
This evolution is related not only to the transformation of
MTX but also to chlorine reduction. Consequently, according
to the additively property of UV absorption spectra, the sub-
traction of the decrease due to chlorine reaction to form the
spectra of themixture allows a better visualization of theMTX
transformation (Fig. 5B). It is characterized by a rapid evolu-
tion of absorbance value at 302 nm during the ﬁrst 50 min.
Such evolution is in close agreement with the results of the
kinetic study of MTX elimination carried out by ﬂuorimetry
(Fig. 3). 50 min is about 2.5 half-life time and therefore at this
moment only 20% of the initial MTX is present. Moreover, the
new peak observed at 263 nm at the beginning of the reaction
disappeared within the ﬁrst 40 min. Contrary to the other
peaks and shoulders, absorbance peaks at 220 and 360 nm of
MTX spectrum appear to increase with time until 150min and
then stabilize. The presence of the isosbestic point already
mentioned shows that there is a quantitative relationship
between the MTX and its transformation product (Pouet et al.,
2004).
3.3. Preliminary identiﬁcation of transformation
products
Considering the removal kinetics and the evolution of UV
spectra (showing shoulder or peak characteristic during the
chlorination), speciﬁc chlorination times (5, 20, 150 and
Fig. 7 e Proposed structures of the observed monochlorinated transformation product and the parent compound MTX.











300 min) were selected for the pre-identiﬁcation of the
transformation products (TPs). According to spectra variation
at 263 nm (Fig. 5A and B), two contact times (5 and 20 min)
were chosen for the identiﬁcation of the by-product produced
during the 40 ﬁrst minutes of chlorination. A 150 min contact
time was chosen in order to identify a potential stable by-
product characterized by the stabilization of absorbance
peaks at 220 and 360 nm. Finally, a contact time of 300 min
was used to identify the compounds present in the mixture at
the end of the reaction. Primary elimination of MTX was
conﬁrmed by LC/MS and only one stable TP seems to be pre-
sent at least until 150 min of chlorination, with a mass spec-
trum corresponding to a chlorinated compound (Fig. 6).
Afterward, the peak intensity of this TP was decreasing.
MTXmass spectra gives a hydrogen adduct as highest peak
(m/z 455). Smaller fragments with m/z 233, 214 etc could be
observed. The transformation product’s highest intensity
mass peak was m/z 489. The retention time was higher, indi-
cating a decrease in polarity.
A ﬁrst assumption could be that the unknown trans-
formation product could be the monochloro-MTX as the MS
signals differ only by a shift between 455 and 489 of the higher
m/z peak the difference of 34 being likely related to either the
substitution of one hydrogen of the two amine functions by
one chlorine atom or the chlorination of the aromatic ring in
ortho position of the amine substituted position. This
outcome needs to be conﬁrmed with further experiments and
analysis.
Furthermore considering the experimental molar ratio of
1:100 for MTX/chlorine, on the one hand, and the chlorine
dose of few mg/L in drinking water treatment (for a residual
concentration of chlorine of 0.2 mg/L for example), on the
other hand, it can be expected that MTX traces found at the
level of ng/L in tap water could be eliminated under actual
conditions, given a contact time of 1 h at least. However this
would result in the formation of transformation products as
found in this study. They have to be better characterized (in
particular in term of related toxicity) for a sound risk
assessment.
3.4. In silico analysis of proposed transformation
products
The results of the applied QSAR modules were expressed in
different ways depending on the software: For Case Ultra
software, the predicted activities of the test chemicals are
expressed as positive, inconclusive (IN(P)) (because both pos-
itive and deactivating alerts were found in the same mole-
cule), inconclusive (IN) (because a signiﬁcant portion of the
test chemical is covered by unknown structural fragments),
negative and out of domain (because unknown structural
fragments were found which exclude the tested molecule
from the chemical space of the training set of the applied
model). For Oasis Catalogic software in the Salmonella Cata-
logic module, the results are expressed as mutagenic or not
mutagenic. For Leadscope software, the predicted activity of
the test chemicals is expressed as positive, negative and not in
domain.
The possible structures of the monochlorinated trans-
formation products together with the parent compound
(Fig. 7) were applied in a set of QSARmodels in order to predict
the activity for different carcinogenic, mutagenic and geno-
toxic endpoints (table 1).
The QSAR analysis provided no clear evidence that the six
chlorination TPs might be increased genotoxic or mutagenic
compared with the parent compound. Particularly, predicted
negativity for bacterial mutagenicity based on the Ames test
was conﬁrmed using three different QSAR platforms: A2H
(Case Ultra, Multicase), SC (Mutagenicity module from Oasis
Catalogic), BM (Bacterial mutagenicity from Leadscope).
Table 1 e In silico predicted toxicity of MTX and its TPs.
QSAR carcinogenicity, genotoxicity and mutagenicity
AOJ A6A A7S A7T A7U A7V A0D ML A08 A64 IVCA MM IVMN
MTX e IN þ þ IN(P)   þ þ IN(P) þ  þ
Chlorine TP1 IN(P) IN þ þ IN(P)   IN(P) OD IN(P) þ  þ
Chlorine TP2 IN(P) IN þ þ IN(P)   IN(P) OD IN(P) þ  þ
Chlorine TP3 IN(P) IN þ þ IN(P)  IN(P) IN(P) IN IN(P) þ  þ
Chlorine TP4 IN(P) IN þ þ IN(P)  IN(P) IN(P) IN IN(P) þ  þ
Chlorine TP5 IN(P) IN þ þ IN(P)  IN(P) IN(P) IN IN(P) þ  þ
Chlorine TP6 OD IN þ IN(P) þ  IN(P) IN(P) IN IN þ þ þ
Calculation has been made with the following QSAR modules: Human Carcinogenicity (A0J), Aneuploidy in Yeast (A6A), Micronucleus For-
mation in vivo composite (A7S), Micronucleus Formation in vivo Mouse (A7T), Chromosome Aberrations in vitro composite (A7U), Chromosome
Aberrations in vitro CHO cells (A7V), Rat Carcinogenicity (A0D), Mouse Lymphoma (ML), Mouse Carcinogenicity (A08), UDS Induction (A64),
In vitro chromosome aberration (IVCA), Mammalian mutagenesis (MM) and In vivo micronucleus (IVMN).
Positive (þ), negative (), inconclusive (IN), inconclusive with positive alert (IN(P)), out of domain (OD).
Table 2 e Positive alerts of MTX and its TPs predicted by




MTX 7, 92, 176, 184 24, 100
Chlorine TP 1 92, 176, 184 100
Chlorine TP 2 92, 176, 184 100
Chlorine TP 3 7, 92, 176 24, 100
Chlorine TP 4 7, 92, 184 24, 100
Chlorine TP 5 7, 92, 176 24, 100
Chlorine TP 6 184 24, 100











Since the alert combinations for micronucleus activity
were altered in four different chlorination isomers, it cannot
be excluded that the micronucleus activity might be modu-
lated after chlorination (table 2). Of note is that ﬁve chlorina-
tion TPs had a positive alert for human carcinogenicity
compared with a negative rating of the parent compound,
although the resulting conclusion of the software was incon-
clusive due to the simultaneous detection of a negative alert.
4. Conclusion
This research demonstrates that a simple experimental
methodology, using basic spectroscopic methods (UV and
ﬂuorimetry) can be useful to monitor the chlorination process
of a methotrexate solution in water. Both chlorine consump-
tion and MTX transformation can easily be followed during
the reaction. A simple kinetic can be proposed with a half life
of 20.6 min for a molar ratio of 1:100 MTX:chlorine. This
ﬁnding is relevant with regard to the residence time of water
and the residual chlorine concentration in distribution
network. The monochloro-MTX is likely to be one of the main
stable transformation product formed during chlorination.
Further experiments with the help of high resolution LC/
MSeMS analysis are required to conﬁrm this result and state
on other potential transformation products. The toxicological
properties of this transformation product should be assessed.
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